Liquidia Corp (LQDA)
12.91
-0.51
(-3.80%)
USD |
NASDAQ |
Jun 14, 12:42
Liquidia Free Cash Flow (Quarterly): -25.49M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -25.49M |
December 31, 2023 | -16.19M |
September 30, 2023 | -22.04M |
June 30, 2023 | -5.807M |
March 31, 2023 | -8.823M |
December 31, 2022 | -5.094M |
September 30, 2022 | -5.868M |
June 30, 2022 | -8.436M |
March 31, 2022 | -9.782M |
December 31, 2021 | -7.579M |
September 30, 2021 | -5.831M |
June 30, 2021 | -8.294M |
March 31, 2021 | -12.44M |
December 31, 2020 | -14.13M |
September 30, 2020 | -12.63M |
Date | Value |
---|---|
June 30, 2020 | -13.52M |
March 31, 2020 | -14.62M |
December 31, 2019 | -14.19M |
September 30, 2019 | -12.59M |
June 30, 2019 | -13.00M |
March 31, 2019 | -10.35M |
December 31, 2018 | -8.430M |
September 30, 2018 | -6.420M |
June 30, 2018 | -7.594M |
March 31, 2018 | -10.26M |
December 31, 2017 | -5.956M |
September 30, 2017 | -6.292M |
June 30, 2017 | -5.493M |
March 31, 2017 | -9.093M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-25.49M
Minimum
Mar 2024
-5.094M
Maximum
Dec 2022
-11.82M
Average
-12.51M
Median
Free Cash Flow (Quarterly) Benchmarks
United Therapeutics Corp | 338.30M |
AIM ImmunoTech Inc | -4.865M |
Perspective Therapeutics Inc | 4.776M |
Protalix BioTherapeutics Inc | 3.59M |
Armata Pharmaceuticals Inc | -10.83M |